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Abstract
 
Polyoma virus is a potent oncogenic pathogen when inoculated into newborn mice of particu-
 
lar H-2
 
k
 
 strains. Using D
 
k
 
 tetramers containing the dominant antipolyoma CD8
 
1
 
 T cell
epitope, middle T protein (MT)389–397, and intracellular interferon 
 
g
 
 staining, we enumer-
ated MT389-specific CD8
 
1
 
 T cells in infected neonates having opposite susceptibilities to
polyoma virus–induced tumors. In resistant mice, MT389-specific CD8
 
1
 
 T cells dramatically
expanded during acute infection in neonates to a frequency rivaling that in adults; furthermore,
in both neonatal and adult mice, this antipolyoma CD8
 
1
 
 T cell response exhibited nearly iden-
tical T cell receptor (TCR) functional avidities and TCR functional fingerprints. Susceptible
mice mounted an MT389-specific CD8
 
1
 
 T cell response of only fourfold lower magnitude
than resistant mice; but, in clear contrast to resistant mice, these CD8
 
1
 
 T cells lacked ex vivo
MT389-specific cytotoxic activity. However, MT389-specific CD8
 
1
 
 T cells in resistant and
susceptible mice expressed similar TCR avidities, perforin levels, and surface type O-glycan
levels indicative of mature CD8
 
1
 
 T cell effectors. Upon in vitro restimulation with infected
antigen-presenting cells, CD8
 
1
 
 T cells from acutely infected susceptible neonates acquired
strong MT389-specific cytotoxicity. These findings indicate that polyoma-specific CD8
 
1
 
 T
cells are armed with, but restrained from deploying, their cytotoxic effector function in mice
susceptible to polyoma virus tumorigenesis.
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Introduction
 
Recent studies have called into question the long-held
concept that neonatal lymphocytes are inherently prone to
induction of tolerance (1–3). Newborn mice inoculated by
certain viruses are capable of generating antiviral CD8
 
1
 
CTLs (3, 4). In addition, several studies have shown that
neonatal DNA vaccination efficiently primes antigen-spe-
cific CD8
 
1
 
 T cell responses and CD4
 
1
 
 T cell–dependent
antibody responses that are long-lived and protect against
virus challenge (5–8). A common feature of nearly all stud-
ies of neonatal T cell responses in vivo, however, is that an-
tigen-specific T cell responses are examined in adulthood,
not during the neonatal period. In particular, no direct in-
formation is available about the magnitude and functional-
ity of antigen-specific T cell responses during neonatal life.
 
Polyoma virus is a potent oncogenic mouse pathogen
when inoculated into newborn mice belonging to particu-
lar inbred strains (9, 10). An essential contribution of T
cells in neonatal mice towards protection against polyoma
virus–induced tumors was provided by early studies show-
ing that neonatal thymectomy enhanced polyoma tumor
susceptibility of otherwise resistant mice (11, 12). High
susceptibility to polyoma virus tumorigenesis is a property
 
of a subset of H-2
 
k
 
 mouse strains (9). We recently found
that the H-2
 
k
 
 MHC and the endogenous mouse mammary
 
tumor provirus, 
 
Mtv-7
 
, are major codeterminants of sus-
ceptibility to polyoma virus–induced tumors (10). This
susceptibility is imparted by the 
 
Mtv-7
 
–encoded superanti-
gen that, by negatively selecting thymocytes bearing par-
 
ticular V
 
b
 
 domains, depletes the peripheral T cell pool in
 
H-2
 
k
 
 mice of polyoma-specific CD8
 
1
 
 T cell precursors,
most of which express Mtv-7 superantigen-reactive V
 
b
 
domains (10). Using polyoma virus–specific CTL cloned
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lines isolated from neonatally infected tumor-resistant H-2
 
k
 
mice, we identified the immunodominant polyoma-spe-
cific CTL epitope as a D
 
k
 
-restricted 9-amino acid peptide
derived from the viral middle T (MT)
 
1
 
 oncoprotein, desig-
nated MT389–397 (13). Interestingly, limiting dilution
analysis revealed that susceptible mice are not entirely de-
void of MT389-specific CTLs but possess 10–20-fold
fewer CTL precursors directed to this epitope than mice
resistant to polyoma virus tumorigenesis (13). The pres-
ence of these antigen-specific CD8
 
1
 
 T cells in mice prone
to develop polyoma tumors is highly reminiscent of the
frequent observation that tumor-specific CD8
 
1
 
 T cells are
detected in the peripheral T cell repertoire of cancer pa-
tients (14–16). A central question, then, is why antipoly-
oma CD8
 
1
 
 T cells in susceptible mice fail to control the
outgrowth of polyoma virus–induced tumors.
Using D
 
k
 
 tetramers containing the MT389–397 peptide,
in conjunction with MT389 peptide-triggered intracellular
IFN-
 
g
 
 production, we visualized dramatic expansion of
antigen-specific CD8
 
1
 
 T cells during acute polyoma infec-
tion in adult mice (17). This MT389-specific CD8
 
1
 
 T cell
expansion was associated with the appearance of strong ex
vivo antigen-specific cytotoxic activity and clearance of in-
fectious polyoma virus. In this study, we applied these sin-
gle cell analyses to enumerate the MT389-specific CD8
 
1
 
 T
cell responses in polyoma virus–infected neonatal mice and
assess their effector functionality directly ex vivo. We
found that tumor-resistant neonatal mice mount a vigor-
ous, cytotoxic and cytokine effector function-competent,
CD8
 
1
 
 T cell response against polyoma virus infection that
rivals that of mice infected in adulthood. In contrast to the
difference in MT389-specific CTL precursor frequency de-
termined by limiting dilution analysis, direct ex vivo analy-
ses revealed that MT389-specific CD8
 
1
 
 T cells attain a
peak expansion in tumor-susceptible mice only fourfold
lower than that of resistant mice. Although these antipoly-
oma CD8
 
1
 
 T cells in susceptible mice retain full capacity
to produce IFN-
 
g
 
, they lack ex vivo cytotoxic effector ac-
tivity. This effector function deficit by antigen-specific
CD8
 
1
 
 T cells likely compromises host defense against
polyoma virus tumorigenesis.
 
Materials and Methods
 
Animals.
 
C3H/HeNCr and CBA/JCr mice were purchased
from the Frederick Cancer Research and Development Center of
the National Cancer Institute. All protocols for animal studies
were approved by the Institutional Animal Care and Use Com-
mittee of Emory University. Pregnant mice were housed in indi-
vidual microisolator cages and monitored daily for births. Adult
mice were used at 6–9 wk of age.
 
Virus and Virus Inoculation.
 
Wild-type polyoma virus, strain
A2, was molecularly cloned and plaque purified, and virus stocks
were prepared on primary baby mouse kidney cells, as described
(13). Adult mice were inoculated subcutaneously in hind foot-
 
pads with 2 
 
3
 
 10
 
6
 
 PFU of virus. Newborn mice were inoculated
subcutaneously in hind footpads with 2 
 
3
 
 10
 
5
 
 PFU of virus
within 12 h of birth.
 
Cell Lines.
 
AG104A cells (18) were maintained in DMEM
containing 5% FCS (Mediatech, Inc.). BALB/3T3 clone A31
cells were obtained from the American Type Culture Collection
and maintained in DMEM containing 5% bovine calf serum
(Summit Biotechnology).
 
Synthetic Peptides.
 
Peptides were synthesized by the solid-
phase method on a Symphony/Multiplex Peptide Synthesizer
(Rainin) with F-moc chemistries. HPLC analysis showed that
peptides were 
 
.
 
90% pure. The following peptides were used in
this study: MT389–397 (RRLGRTLLL) and a panel of ala-
nine monosubstituted MT389–397 analogue peptides. Peptides
were diluted in 10% serum-containing medium immediately be-
fore use.
 
Polyoma Virus Plaque Assay.
 
Spleens were snap-frozen in
sterile Kontes tubes (Kontes Glass Company), adjusted to 50 mg/
ml in DMEM at 4
 
8
 
C, and homogenized using an overhead stirrer
(Wheaton) and disposable Teflon pestles (Kontes). Homogenized
tissues were freeze–thawed three times, incubated for 45 min at
42
 
8
 
C, and centrifuged to remove cell debris. Supernatants were
titered for infectious virus by plaque assay on BALB/3T3 clone
A31 cells as described (17). The detection limit for this plaque as-
say is 1 PFU/mg spleen.
 
51
 
Cr Release Assay.
 
Peptide-pulsed 
 
51
 
Cr-labeled AG104A
(H-2
 
k
 
, class II MHC-negative) target cells were prepared as de-
scribed (13), and aliquoted at 5,000 cells/well into U-bottom 96-
well microtiter plates (Costar). Single cell suspensions of spleens
were treated with RBC lysing buffer (Sigma-Aldrich), and viable
mononuclear cells aliquoted at the indicated E/T ratios. After a
5-h incubation at 37
 
8
 
C, half the volume of each well was re-
moved and counted in a 1470 Wallac Wizard gamma counter.
Values for percent specific lysis were calculated as described
(17). Spontaneous 
 
51
 
Cr release from target cells in all assays was
 
,
 
15% of total 
 
51
 
Cr release. Percent specific lysis values represent
mean values of quadruplicate wells. SEMs were always 
 
,
 
5% of
the mean values and are omitted.
 
Flow Cytometry.
 
Single cell suspensions of spleen were pre-
pared, RBCs lysed, and 10
 
6
 
 cells stained in phenol red–free
RPMI 1640 (Life Technologies) containing 2% FCS and 0.1%
sodium azide (FACS
 
®
 
 buffer) for 1 h at 4
 
8
 
C, followed by three
washes in FACS
 
®
 
 buffer and fixation in PBS containing 1%
paraformaldehyde. Cells were surface-stained with PE- or Tri-
color-conjugated rat anti–mouse CD8
 
a
 
 mAb (clone CT-CD8a;
Caltag) and FITC-conjugated rat anti–mouse CD11a, CD43
(1B11), or 
 
a
 
/
 
b 
 
TCR mAbs (BD PharMingen), and allophycocy-
anin-conjugated D
 
k
 
/MT389 tetramers. H-2D
 
k
 
 tetramers contain-
ing the MT389–397 peptide or the gag88–96 peptide
(RRKGKYTGL), a retroviral CTL epitope (19), were prepared
and their specificity verified as described (17, 20). Samples were
acquired on a FACSCalibur™ (Becton Dickinson), and data ana-
lyzed using CELLQuest™ (Becton Dickinson) and FlowJo soft-
ware (Tree Star, Inc.). Plots are gated on CD8
 
1
 
 T cells and values
shown are the percentages of CD8
 
1
 
 T cells in the indicated quad-
rant. Of necessity, different litters of neonatally inoculated mice
were used for each of the time points for the kinetic analyses of
MT389-specific CD8
 
1
 
 T cell responses (see Figs. 2 and 5); there-
fore, gates for each postinfection time point were individually as-
signed based on analysis of CD8
 
1
 
 T cells from uninfected mice.
For FACS
 
®
 
 sorting, RBC-lysed spleen cells were stained in
phenol red–free RPMI 1640 plus 2% FCS (FACS
 
®
 
-sorting
buffer) containing PE-conjugated anti-CD8
 
a
 
, FITC-conjugated
 
1
 
Abbreviations used in this paper:
 
 ELISPOT, enzyme-linked immunospot;
MT, middle T protein. 
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anti–
 
a
 
/
 
b 
 
TCR, and allophycocyanin-conjugated D
 
k
 
/MT389
tetramers for 1 h at 4
 
8
 
C. Cells were washed and resuspended in
FACS
 
®
 
-sorting buffer, then sorted on a FACS Vantage™ (Bec-
ton Dickinson).
 
Intracellular IFN-
 
g
 
 and Perforin Staining.
 
RBC-lysed spleen
cells were cultured for 5 h in 96-well flat-bottom microtiter
plates (Costar) at 10
 
6
 
 cells/well in 0.2 ml/well IMDM (Life
Technologies) containing 10% FCS, 50 
 
m
 
M 2-ME, and penicil-
lin/streptomycin, and supplemented with 1 
 
m
 
g/ml brefeldin A
(Sigma-Aldrich), 50 U/ml human rIL-2 (BD PharMingen), and
synthetic peptides at 10 
 
m
 
M. Cells were then surface stained with
PE-conjugated rat anti–mouse CD8
 
a
 
 mAb (Caltag) and allophy-
cocyanin-conjugated D
 
k
 
/MT389 tetramers. After washing, cells
were permeabilized and stained for intracellular IFN-
 
g
 
 with
FITC-conjugated rat anti–mouse IFN-
 
g
 
 mAb (clone XMG1.2;
BD PharMingen) or its isotype control Ab (rat IgG1; BD Phar-
Mingen) using the Cytofix/Cytoperm kit, according to the man-
ufacturer’s instructions (BD PharMingen).
For intracellular perforin staining, RBC-lysed spleen cells were
surface stained with allophycocyanin-conjugated D
 
k
 
/MT389 tet-
ramers for 30 min at 4
 
8
 
C. Cells were then fixed, permeabilized,
and stained with rat anti–mouse perforin mAb (clone P1-8; Ka-
miya Biomedical Co.) or isotype-matched control Ab (rat IgG2a;
Caltag), washed, then stained with PE-conjugated donkey anti–
rat F(ab
 
9
 
)
 
2
 
 IgG (Jackson ImmunoResearch Laboratories) using
the FIX & PERM cell permeabilization kit, according to the
manufacturer’s instructions (Caltag). Finally, cells were stained
with FITC-conjugated rat anti–mouse CD8
 
a
 
 mAb (Caltag).
 
Single Cell Enzyme-linked Immunospot Assay for IFN-
 
g
 
–secreting
Cells.
 
Pooled spleens from four newborn inoculated 13-d-old
C3H/HeN mice were stained with anti-CD8
 
a
 
, anti–
 
a
 
/
 
b 
 
TCR,
and D
 
k
 
/MT389 tetramers and sorted by flow cytometry into
three distinct populations, as described in Fig. 4. Each sorted pop-
ulation was serially diluted threefold in wells previously coated
with rat anti–mouse IFN-
 
g
 
, to which were then added 5 3 105
g-irradiated (2,000 rad) syngeneic cells and MT389–397 peptide
(0.1 mg/ml) or no peptide. After 36 h incubation at 378C, single
cell IFN-g enzyme-linked immunospot (ELISPOT) assays were
performed as described (21).
Results
Ex Vivo Polyoma-specific Cytotoxic Activity in Neonatally In-
fected Resistant Mice. Polyoma virus–specific CTL cloned
lines are readily isolated from newborn inoculated mice of
H-2k strains resistant to polyoma virus–induced tumors;
these CTL lines are predominantly directed toward the Dk-
restricted MT389–397 epitope (13). Freshly explanted
spleen cells from acutely infected adult C3H/HeN mice, a
strain resistant to polyoma virus–induced tumors when in-
oculated at birth, exhibit high levels of MT389-specific cy-
totoxic activity (17). We asked whether MT389-specific
CTL activity could be similarly detected ex vivo during
acute infection in newborn inoculated C3H/HeN mice.
As shown in Fig. 1 A, freshly explanted spleen cells from
C3H/HeN mice inoculated at birth efficiently lysed
MT389 peptide-coated syngeneic target cells. MT389-spe-
cific lysis was detected as early as day 8 of age, peaked at
day 13 after infection, and was nearly undetectable by 3 wk
of age (Fig. 1 A, and data not shown). Spleen cells from na-
ive 13-d-old C3H/HeN mice did not lyse MT389-pulsed
target cells (data not shown). The emergence of MT389-
specific cytotoxicity in neonatal mice, as previously seen in
adult infected mice (17), is associated with clearance of in-
fectious polyoma virus (Fig. 1 B).
In Vivo Visualization of the MT389-specific CD81 T Cell
Response in Neonatal C3H/HeN Mice. Using Dk/MT389
tetramers and intracellular staining for MT389-stimulated
IFN-g, we showed that adult C3H/HeN mice mount
large-scale expansion of antigen-specific CD81 T cells dur-
ing acute polyoma virus infection (17). The potent ex vivo
antipolyoma cytotoxic activity expressed by newborn in-
fected C3H/HeN mice suggested that neonatal and adult
mice mount similarly massive expansions of MT389-spe-
cific CD81 T cells to polyoma virus infection. As shown in
Fig. 2 A, by 8 d of age, newborn inoculated C3H/HeN
mice generated a population of antigen-specific CD81 T
cells readily detected by Dk/MT389 tetramers. By day 13
after infection, these tetramer1CD81 T cell numbers had
expanded to a point where they constituted nearly one-
third of the CD81 T cells in the spleen that expressed high
levels of CD11a, a phenotype for antigen-experienced T
cells. Even by day 50, in the absence of detectable infec-
tious virus in the spleen, MT389-specific CD81 T cells still
represented nearly 20% of activated CD81 T cells. The
Figure 1. Kinetic analyses of
ex vivo MT389-specific cyto-
toxic activity and virus titer in
polyoma-infected C3H/HeN
mice. (A) Spleen cells from
newborn inoculated mice were
assayed at the indicated day after
infection for lysis of 51Cr-
labeled syngeneic target cells
pulsed with MT389 peptide (10
mM). Each value represents the
mean 6 SEM percent specific
lysis by spleen cells of three to
four individual mice; results are
representative of three experi-
ments. No lysis of unpulsed target cells was seen by spleen cells from
these infected mice at any postinfection time point, and spleen cells
from naive neonatal and adult C3H/HeN mice did not lyse MT389
peptide-pulsed targets (reference 17, and data not shown). (B) Spleens
from newborn inoculated mice of the indicated ages were harvested,
homogenized, and titered for polyoma virus by plaque assay. Each value
represents the mean 6 SD PFU/mg spleen from five to six individual
mice. *, below detection limit of 1 PFU/mg.598 Polyoma Virus–specific CD81 T Cell Responses in Neonatal Mice
specificity of Dk/MT389 tetramers for spleen cells from
acutely infected neonatal C3H/HeN mice was confirmed
(a) by lack of staining by control Dk/gag88 tetramers, as
previously shown in acutely infected adult C3H/HeN
mice (17), and (b) by lack of Dk/MT389 tetramer staining
when C3H/HeN neonates were inoculated with a replica-
tion-competent mutant polyoma virus carrying substitu-
tions in the MT389–397 sequence that abrogate recogni-
tion by MT389-specific CD81 T cells (data not shown).
Enumeration of MT389-specific CD81 T cells in acutely
infected neonatal mice by peptide-stimulated intracellular
IFN-g production revealed an unexpected discordance
with Dk/MT389 tetramers in detecting antigen-specific
CD81 T cells. As shown in Fig. 2 B, at 8 and 13 d of age
of newborn inoculated C3H/HeN mice, 25–30% more
MT389-specific CD81 T cells were detected by intracellu-
lar IFN-g staining than by tetramer binding. Note that
most of the IFN-g1 CD81 T cells show decreased tetramer
staining as a result of ligand-induced TCR downmodula-
tion. Interestingly, this quantitative discrepancy between
tetramer and intracellular IFN-g staining for antigen-spe-
cific CD81 T cells resolves at time points after clearance of
detectable infectious virus in the spleen. Because the MHC
anchoring residues for peptides bound to Dk and Kk are dis-
tinct (P2 5 basic residue for Dk, but acidic residue for Kk;
references 13 and 22), it is highly unlikely that Kk presents
the MT389–397 peptide to CD81 T cells and is responsible
for amplifying the number of IFN-g1CD81 T cells. Fur-
thermore, spleen cells from acutely infected neonate and
adult C3H/HeN mice lyse MT389 peptide-pulsed target
cell lines of C3H.OL (KdDk), but not B10.A (KkDd), origin
(references 13 and 23; data not shown).
Figure 2. Visualization of MT389-spe-
cific tetramer1CD81 T cells during poly-
oma infection in neonatal C3H/HeN mice.
(A) Spleen cells from newborn inoculated
mice at each of the indicated ages were
stained with Dk/MT389 tetramers, and
anti-CD8a and anti-CD11a mAbs, and an-
alyzed by flow cytometry. Plots are gated on
CD81 T cells and values shown are the per-
centages of CD81 T cells in the indicated
quadrant. (B) Spleen cells from neonatally
infected mice were cultured in the absence
or presence of MT389 peptide (10 mM) for
5 h, surface-stained with Dk/MT389 tet-
ramers and anti-CD8a, then stained for in-
tracellular IFN-g. FITC-conjugated iso-
type control Ab for the anti–IFN-g mAb
did not stain MT389 peptide-stimulated
spleen cells from acutely infected neonatal
C3H/HeN mice (data not shown). Plots are
gated on CD81 T cells and the values
shown are the percentages of CD81 T cells
in the indicated quadrant. A naive 13-d-old
C3H/HeN mouse is included as a specific-
ity control. Plots are representative of three
experiments using three to five mice per
time point.
Table I. Comparison of MT389-specific CD81 T Cells in Infected Neonate and Adult C3H/HeN Mice
Neonate Adult
MT389-specific
IFN-g cells Day 8 Day 13 Day 23 Day 50 Day 5 Day 7 Day 12 Day 50
Total (3106) 0.10 6 0.02 1.39 6 0.27 0.31 6 0.03 0.14 6 0.04 0.8 6 0.09 3.81 6 0.40 2.09 6 0.17 1.06 6 0.08
Percent 
CD81 cells 20.2 6 4.0 40.7 6 2.9 6.8 6 0.3 1.7 6 0.3 8.2 6 0.6 23.9 6 1.8 15.2 6 0.2 7.1 6 0.6
Spleen cells from polyoma virus–inoculated mice at the indicated day after infection were stimulated with MT389 peptide for 5 h, then surface stained
with PE-conjugated anti-CD8a, stained intracellularly with FITC-conjugated anti–IFN-g, and analyzed by flow cytometry. No IFN-g was produced
by MT389 peptide–stimulated spleen cells from naive neonate and adult mice (data not shown). Values represent the mean 6 SEM of gated CD81
populations of three to six mice at each time point from three separate experiments.599 Moser et al.
As staining with Dk/MT389 tetramers underestimated
the actual number of MT389-specific CD81 T cells in vivo
in acutely infected neonatal mice, total numbers of
MT389-specific CD81 T cells were determined by intra-
cellular IFN-g staining (Table I). Due to technical limita-
tions associated with the very small number of T cells in
the neonatal spleen, MT389-specific CD81 T cells could
not be reliably detected under day 8 of age. However, even
by day 8, one in five splenic CD81 T cells in newborn in-
oculated C3H/HeN mice was found to recognize the
dominant MT epitope; this frequency matches that seen at
the peak expansion of MT389-specific CD81 T cells dur-
ing acute infection in adult C3H/HeN mice. Remarkably,
by day 13 of age, z40% of the splenic CD81 T cells in
neonatal C3H/HeN mice recognize the MT389 epitope.
The larger viral load during acute infection in neonates
than in adults may promote this more vigorous expansion
of antipolyoma CD81 T cells in newborn inoculated mice.
Substantial numbers of MT389-specific CD81 T cells also
persist in memory (day 50 after infection) in mice of both
inoculation age groups, although differences in size be-
tween their respective antipolyoma memory CD81 T cell
pools roughly correspond to differences in maximal expan-
sion during acute infection.
Tetramer-negative Antigen-specific CD81 T Cells in Neona-
tally Infected Mice. Because low-affinity TCR show re-
duced levels of tetramer binding and faster tetramer dissoci-
ation rates (24, 25), we asked whether low TCR affinity
accounted for the higher frequency of antigen-specific
CD81 T cell effectors detected by intracellular IFN-g
staining than by tetramer binding in the infected neonatal
mice. In acutely infected adult mice, enumeration of
MT389-specific CD81 T cells by tetramer binding and
peptide-induced intracellular IFN-g production closely
correspond (17). Therefore, the TCR avidity of adult ver-
sus neonate MT389-specific CD81 T cells was compared.
Spleen cells from C3H/HeN mice at time point of peak ex
vivo cytotoxic activity after newborn (day 13 after infec-
tion) and adult (day 8 after infection) virus inoculation
were assayed for peptide dose dependence of target cell ly-
sis. Because the spleens of neonate- and adult infected mice
at these respective time points contain different numbers of
MT389-specific CD81 T cells, the extent of target cell lysis
at each peptide titration was normalized to equivalent
numbers of MT389-specific CD81 T cells. As shown in
Fig. 3 A, C3H/HeN mice inoculated at birth or as adults
generated MT389-specific CTL effectors with virtually
equivalent functional TCR avidity.
To explore whether MT389-specific CD81 T cells gen-
erated in infected adult and neonates differed in fine speci-
ficity for the MT389 epitope, we also compared the capac-
ity of alanine monosubstituted MT389 analogue peptides
to stimulate IFN-g production by freshly explanted spleen
cells from acutely infected neonate and adult C3H/HeN
mice. We previously showed that each of these analogue
peptides bound to purified Dk molecules with affinity
equivalent to the wild-type peptide (20). As shown in Fig.
3 B, remarkably little variation in TCR functional finger-
prints was observed not only between individual mice of
the same inoculation age group, but also between the neo-
natal and adult infected mice. In line with their similar fine
specificity profiles, Dk/MT389 tetramer1CD81 T cells in
acutely infected neonatal C3H/HeN mice showed the
same Vb6- and Vb8.1-dominated repertoire as adult C3H/
HeN mice (reference 17, and data not shown).
We next asked whether subpopulations of MT389-spe-
cific CD81 T cells may be present in acutely infected neo-
natal mice that express TCRs at levels unfavorable for effi-
cient tetramer binding, but sufficient to trigger T cell
activation. Pooled spleen cells from 13-d-old newborn in-
Figure 3. Comparison of TCR avidities and functional fingerprints of
MT389-specific CD81 T cells from newborn and adult inoculated C3H/
HeN mice. (A) Spleen cells from adult and neonatally infected mice at the
peak of their antigen-specific CTL response (day 7 and day 13 after infec-
tion, respectively) were assayed in a 51Cr release assay with syngeneic tar-
get cells pulsed with serial log dilutions of the MT389 peptide. Values
represent the mean 6 SEM percent specific lysis of three mice normalized
to 104 antigen-specific CD81 cells, as determined by intracellular IFN-g
staining. (B) Spleen cells from day 7 and day 13 postinfection adult and
neonatal mice, respectively, were stimulated for 5 h with wild-type
MT389 peptide (10 mM) or with each of a panel of alanine monosubsti-
tuted MT389 peptides (10 mM), then stained for intracellular IFN-g. The
level of stimulation at each substituted peptide is presented as the percent-
age of the number of IFN-g1CD81 cells with respect to that seen with
the wild-type peptide. Letters in parentheses indicate the amino acids at
each of the positions in the wild-type peptide. Results are representative
of three experiments.600 Polyoma Virus–specific CD81 T Cell Responses in Neonatal Mice
oculated C3H/HeN mice were triple stained with Dk/
MT389 tetramers, anti-CD8a and anti-ab TCR mAbs,
and analyzed by flow cytometry. As shown in Fig. 4 A,
there was a discrete population of tetramer2CD81 T cells
that had poor to absent a/b TCR expression. This a/b
TCRlow/2 T cell population also expressed high levels of
the activation marker CD11a (data not shown). To evalu-
ate whether polyoma-specific CD81 T cells resided within
this a/b TCRlow/2tetramer2 population, three CD81 T
cells populations were FACS® sorted based on tetramer and
a/b  TCR expression, and MT389-specific cells then
counted by IFN-g ELISPOT assay. As shown in Fig 4 B,
the sorted Dk/MT389 tetramer1 population showed a near
1 to 1 correspondence between number of cells plated and
the number of spots identified when stimulated with the
MT389 peptide, whereas no MT389-stimulated IFN-g se-
cretion was detected by the a/b TCR1tetramer2 popula-
tion. Interestingly, approximately one-third of the a/b
TCRlow/2tetramer2 cells contained MT389-specific CD81
T cells (Fig. 4 B).
MT389-specific CD81 T Cell Expansion in Neonatal Mice
Susceptible to Polyoma Virus–induced Tumors. Because new-
born inoculated H-2k mice carrying the Mtv-7 provirus are
susceptible to polyoma virus–induced tumors (10), we ap-
plied tetramer and intracellular IFN-g staining to attempt
to visualize MT389-specific CD81 T cells in acutely in-
fected neonatal mice of an H-2k  Mtv-71 inbred strain,
CBA/J. As shown in Fig. 5, both of these single cell meth-
odologies detected antigen-specific CD81 T cells in in-
fected CBA/J neonatal mice, but their frequency was
clearly lower than in the neonatally infected resistant C3H/
HeN mice at each of the same postinfection time points
(Fig. 2 B). Like C3H/HeN infected neonates, maximal ex-
pansion of MT389-specific CD81 T cells was reached by
13 d of age in newborn inoculated CBA/J mice (Fig. 5,
and data not shown). It is interesting to note that at this
time point tetramer staining also accounts for only about
two-thirds of the MT389 peptide-stimulated IFN-g1
CD81 T cells. Importantly, despite the opposite suscepti-
bilities of these two inbred mouse strains, total splenic
MT389-specific CD81 T cells in the resistant C3H/HeN
neonates at day 13 after infection were only fourfold higher
than in the infected susceptible CBA/J neonates at this age
(Fig. 6).
CBA/J neonates were also considerably less efficient in
eliminating infectious polyoma virus than C3H/HeN
mice. Although splenic virus titers were equivalent at early
stages of infection in neonatal mice of each strain, 8-d-old
CBA/J mice possessed 10-fold higher levels of infectious
virus in their spleens, with significant viral titers detected at
least through day 23 after infection (Fig. 7). This higher
peak and substantially longer sustained virus levels in neo-
Figure 4. TCRlow MT389-specific CD81 T cells in acutely infected
neonatal mice. (A) Spleen cells from a 13-d-old newborn inoculated
C3H/HeN mouse were stained with anti-CD8a, anti–a/b TCR, and
Dk/MT389 tetramers directly ex vivo. The plot is gated on CD81 T cells
and values shown are the percentages of CD81 T cells in the indicated
quadrant. Plot is representative of six mice in two experiments. (B) Pooled
spleen cells from four 13-d-old newborn inoculated C3H/HeN mice
were stained as in A, and three CD81 T cell populations sorted as indi-
cated. Each population was aliquoted in the presence of irradiated syn-
geneic unpulsed or MT389 peptide-pulsed feeder cells in an IFN-g
ELISPOT assay. In the absence of peptide, no IFN-g–producing cells
were detected in any of these FACS®-sorted populations (data not shown).
Figure 5. Visualization of MT389-specific CD81 T cells
in neonatally infected CBA/J mice by intracellular IFN-g
staining. Spleen cells from polyoma virus–infected neonatal
mice were stained with Dk/MT389 tetramers and anti-
CD8a mAb, followed by staining for intracellular IFN-g.
Plots are gated on CD81 T cells and the values shown are
the percentages of CD81 T cells in the indicated quadrant.
Plots are representative of three independent experiments
using three to five mice per time point.601 Moser et al.
natal CBA/J mice may, in fact, have also provided an anti-
genic stimulus to boost the size of the CBA/J memory
CD81 T cell pool, which was of nearly the same size as
C3H/HeN neonates (Fig. 6).
Infected CBA/J Neonates Lack Ex Vivo MT389-specific Cy-
totoxic Activity. Although functionally competent to pro-
duce IFN-g, we asked whether MT389-specific CD81 T
cells generated by newborn inoculated CBA/J mice also
possess antigen-triggered cytotoxic activity. As shown in
Fig. 8, freshly explanted spleen cells from acutely infected
CBA/J neonates exhibited no detectable lysis against
MT389 peptide-pulsed syngeneic target cells. The trivial
explanation that expansion of MT389-specific CD81 T
cells was insufficient to permit detection of ex vivo target
lysis is highly unlikely because, even at 13 d of age, CBA/J
neonatal spleens contained slightly more MT389-specific
CD81 T cells (5,856 6 60 cells/well at E:T 5 400:1) than
those of 8-d-old infected C3H/HeN mice (4,040 6 120
cells/well at E:T 5 400:1), which exhibit significant anti-
gen-specific cytotoxicity (Fig. 1 A). Furthermore, competi-
tion between infected cells in the CBA/J neonate spleen
and 51Cr-labeled targets for CTL effectors is ruled out be-
cause spleen cells from 13-d-old newborn infected CBA/J
mice (z2,500 PFU/mg spleen) did not inhibit MT389-
specific ex vivo CTL activity by day 8–infected adult
C3H/HeN mice (data not shown). That polyoma-infected
CBA/J mice are not inherently defective in generating ex
vivo MT389-specific cytotoxic activity is illustrated by the
capacity of spleen cells from acutely infected adult CBA/J
mice to lyse MT389 peptide-loaded target cells. Impor-
tantly, the defect in ex vivo cytotoxic effector function by
MT389-specific CD81 T cells in acutely infected CBA/J
neonatal mice is reversed upon in vitro antigen restimula-
tion (Fig. 8).
Because reduced CTL activity may reflect low TCR
avidity (24, 26), we investigated whether acutely infected
C3H/HeN and CBA/J neonates generate MT389-specific
CD81 T cells differing in TCR avidity. Spleen cells from
13-d-old newborn inoculated C3H/HeN and CBA/J
mice, the age for peak expansion of MT389-specific CD81
T cells in infected neonates of each strain, were stimulated
with graded doses of antigenic peptide for 5 h, then stained
for intracellular IFN-g. Comparison of IFN-g1CD81 T
cell numbers at each peptide concentration as a percentage
of maximal MT389 peptide stimulation revealed no major
differences in functional TCR avidity by the MT389-spe-
cific CD81 T cells generated in these polyoma tumor–resis-
tant and susceptible mice (Fig. 9 A).
We then asked whether the absence of ex vivo CTL ac-
tivity by MT389-specific CD81 T cells in infected CBA/J
neonates reflected reduced intracellular perforin levels. Re-
peated encounter with infected cells in vivo, such as in
acutely infected CBA/J neonatal mice, could conceivably
result in large-scale degranulation by antiviral CTL effec-
tors; the consequent deficit in intracellular perforin-
granzyme stores would impair ex vivo cytotoxic activity.
However, Fig. 9 B shows that MT389-specific CD81 T
cells in newborn inoculated 13-d-old C3H/HeN and
Figure 6. Comparison of the magnitude of MT389-specific CD81 T
cell responses by newborn inoculated C3H/HeN and CBA/J mice. To-
tal numbers of splenic MT389-specific CD81 T cells, as determined by
intracellular IFN-g staining, were determined for mice of each strain at
the indicated ages. Values represent the mean 6 SEM of three to five
mice at each time point. Results are representative of two independent
experiments.
Figure 7. Kinetic analysis of
virus titers in newborn inocu-
lated CBA/J mice. Spleens from
neonatally infected mice were
harvested, homogenized, and ti-
tered for polyoma virus by
plaque assay. Each value repre-
sents the mean 6 SD PFU/mg
spleen from five to six individual
mice. *, below detection limit of
1 PFU/mg.
Figure 8. Kinetic analysis of ex vivo MT389-specific cytotoxic activity
in newborn inoculated CBA/J mice. Spleen cells from neonatal CBA/J
mice at the indicated days after infection and day 6 postinfection adult
mice were assayed for lysis of 51Cr-labeled syngeneic target cells pulsed
with MT389 peptide (10 mM). Spleen cells from 13-d-old newborn in-
oculated mice were also cocultured for 5 d with polyoma-infected irradi-
ated syngeneic spleen cells, then assayed for lysis of MT389-pulsed target
cells. Each value represents the mean 6 SEM percent specific lysis by
spleen cells of four to five infected neonatal mice and three adult inocu-
lated mice; results are representative of four independent experiments. No
lysis of unpulsed target cells was seen by spleen cells from these infected
mice at any postinfection time point, and spleen cells from naive neonatal
and adult CBA/J mice did not lyse MT389 peptide-pulsed targets (data
not shown).602 Polyoma Virus–specific CD81 T Cell Responses in Neonatal Mice
CBA/J mice each express levels of intracellular perforin
similar to those from day 7 postinfection adult C3H/HeN
mice, which exhibit peak ex vivo MT389-specific cyto-
toxic activity (17).
Finally, we explored the possibility that MT389-specific
CD81 T cells in CBA/J neonates occupy a preeffector
maturation stage. MT389-specific CD81 T cells in both
newborn inoculated C3H/HeN and CBA/J neonates
nearly uniformly express upregulated surface levels of
CD11a (Fig. 2 A, and data not shown), indicative of an ef-
fector/memory T cell phenotype. To distinguish between
effector and memory T cells, we made use of the 1B11
mAb, which recognizes a type O-glycan epitope selectively
upregulated on the cell surface of effector CD81 T cells
(27). As shown in Fig. 9 C, MT389-specific CD81 T cells
in 13-d-old infected CBA/J mice are virtually all 1B11hi.
Dk/MT389 tetramer1 cells in 13-d-old C3H/HeN neo-
nates showed mixed 1B11 expression levels, consistent
with an effector to memory T cell transition once virus is
cleared (Fig. 1 B); in 10-d-old C3H/HeN neonates, when
infectious virus is still detected in the spleen, most of the
MT389-specific CD81 T cells are 1B11hi. Taken together,
these findings support the conclusion that MT389-specific
CD81 T cells in acutely infected CBA/J neonates are cyto-
toxic effectors that fail to express this critical antiviral/tu-
mor activity in vivo.
Discussion
In this study, we present quantitative in vivo evidence
that neonatal mice are capable of mounting a dramatic
functional antigen-specific CD81 T cell response to a sys-
temic virus infection. Using both Dk tetramers containing
the immunodominant polyoma virus–specific CD81 T cell
epitope, MT389–397, and intracellular IFN-g staining of
MT389 peptide-stimulated T cells, we visualized massive
expansion of antipolyoma CD81 T cells in mice inoculated
at birth to levels comparable to that of adult inoculated
mice. In mice belonging to an inbred strain resistant to
polyoma virus–induced tumors, this antigen-specific CD81
T cell response was temporally associated with the emer-
gence of ex vivo MT389-specific cytotoxic activity and
rapid clearance of infectious polyoma virus. In contrast,
mice susceptible to polyoma virus tumorigenesis cleared vi-
rus at a markedly slower rate, and, although capable of gen-
erating MT389-specific CD81 T cells, these T cells ex-
hibited a selective functional deficit in antigen-induced
cytotoxic activity.
Striking similarities were observed in the MT389-spe-
cific CD81 T cell response in the polyoma tumor–resistant
C3H/HeN mice inoculated at birth and as adults. As a per-
centage of splenic CD81 T cells, the peak expansion of
MT389-specific CD81 T cells in neonatally infected tu-
mor-resistant mice, in fact, attained nearly twice the mag-
nitude of that seen in adult infected mice. Consistent with
our previous finding that the size of the MT389-specific
CD81 T cell expansion varies directly with the viral load
(28), the higher level infection in newborn inoculated than
adult inoculated mice is likely responsible for this larger ex-
pansion in neonatal mice. Moreover, taking into account
the fact that the neonatal spleen contains ,1% of the T
cells of the adult spleen (29), the rate of expansion of anti-
gen-specific CD81 T cells in neonatal mice most likely ex-
ceeds that of adult mice. It is also interesting to note that
there is a similar relationship between clonal burst size and
size of the memory T cell pool for MT389-specific CD81
T cell responses in infected adult and neonatal mice. In
newborn inoculated mice, the influx of recent thymic T
Figure 9. Comparison of TCR functional avidities and phenotypic
maturation of MT389-specific CD81 T cells in infected C3H/HeN and
CBA/J neonatal mice. (A) Spleen cells were harvested from 13-d-old
newborn inoculated mice of each strain, stimulated for 5 h with serial log
dilutions of MT389 peptide, then stained for intracellular IFN-g. The ef-
ficiency of stimulation at each peptide concentration is presented as the
percentage of the number of IFN-g1CD81 cells with respect to that at
the maximal stimulating peptide dose (10 mM). Each value represents the
mean 6 SEM of three mice, and results are representative of two experi-
ments. (B) Spleen cells from day 13 postinfection C3H/HeN and CBA/J
neonate and day 7 postinfection C3H/HeN adult mice were surface-
stained with Dk/MT389 tetramers, permeabilized, then stained for per-
forin and CD8. Plots are gated on Dk/MT389 tetramer1CD81 T cells,
with dashed lines indicating staining with an isotype-matched control Ab
and solid lines indicating antiperforin mAb staining. Each plot is represen-
tative of five mice. (C) Surface staining of spleen cells with Dk/MT389
tetramer, and anti-CD8a, and anti-CD43 (1B11) mAbs. Plots are gated
on CD81 cells, and each is representative of four to five mice.603 Moser et al.
cell emigrants seeding the peripheral T cell pool after viral
clearance most likely accounts for the comparatively low
representation of MT389-specific memory CD81 T cells
among the total splenic CD81 T cell population; however,
this peripheral seeding is not accompanied by dramatic at-
trition of the memory MT389-specific CD81 T cell pool.
MT389-specific CD81 T cells in mice of both age groups
also share TCR functional avidity, near matches in their
TCR functional fingerprints, and nearly identical Vb rep-
ertoires. The finding that the postinfection time point for
initial detection of MT389-specific CD81 T cells differed
by only 2–3 d between newborn inoculated and adult in-
oculated mice further suggests that the MT389-specific
CD81 T cell response in neonatal mice resulted from the
priming of T cells in newborn mice, rather than from its
delayed induction by viral antigens in more mature mice.
We unexpectedly found major differences in the capac-
ity of tetramer binding and antigen-stimulated intracellular
IFN-g production to identify polyoma-specific CD81 T
cells during acute infection in neonatal mice. Approxi-
mately one-third of MT389-specific CD81 T cells in
acutely infected neonatal mice expressed TCRs at a level
apparently insufficient for stable tetramer binding, but suffi-
cient to exceed the minimum threshold of TCR occu-
pancy required to trigger T cell activation; these tetramer-
negative T cells largely account for the discordance
between tetramer and intracellular cytokine staining in de-
tecting antigen-specific CD81 T cells. Several observations
favor the concept that this TCRlow/2 population of
MT389-specific CD81 T cells results from TCR down-
modulation, likely driven by repetitive TCR encounter
with Dk/MT389-expressing cells during acute polyoma vi-
rus infection. First, once virus is cleared, differences be-
tween tetramer binding and intracellular cytokine staining
in visualizing antigen-specific CD81 T cells tend to re-
solve. Also, in acutely infected adult mice, where peak lev-
els of polyoma virus are 10-fold lower than in neonatal
mice, these two single cell flow cytometry approaches
show closer correspondence in their sensitivity for detect-
ing MT389-specific CD81 T cells (17). The possibility that
neonatal mice, in contrast to adult mice, intrinsically pos-
sess TCRlow/2 and TCRhighCD81 T cell subpopulations is
also unlikely, as no differences in a/b TCR expression by
CD81 T cells were seen between uninfected 13-d-old and
adult C3H/HeN mice (data not shown). Although our
findings implicate TCR downmodulation as the likely ex-
planation for the inability of tetramers to stain all antigen-
specific T cells, alternative mechanisms may also be opera-
tive, including the generation of antiviral CD81 T cell
populations during acute infection that express TCRs of
weak avidity, or of a conformation or cell surface distribu-
tion unfavorable for stable tetramer binding (24, 30).
Our findings suggest that small differences in the magni-
tude of the antiviral CD81 T cell response in the face of
high viral load may determine their cytotoxic effector
functionality. Mtv-7 superantigen-mediated deletion of
thymocytes expressing Vb6 and Vb8.1, the predominant
Vb members used by MT389-specific CD81 T cells in re-
sistant mice (13, 17), reduces the number of MT389-spe-
cific CD81 T cell clones in the naive T cell repertoire of
susceptible mice. Thus, inheritance of this endogenous Mtv
provirus is likely to be a major determinant of polyoma tu-
mor susceptibility (10). Given the considerably lower num-
ber of splenic T cells in neonatal versus adult mice (29), dif-
ferences between Mtv-71 and Mtv-72 H-2k mice in the size
of the precursor antipolyoma CD81 T cell pool, coupled
with the higher viral load in neonates, may magnify the
importance of small differences in MT389-specific CD81
T cell numbers in neonatally infected mice for defense
against primary polyoma virus infection. It is important to
point out that because the H-2k mice used in this study are
not congenic for Mtv-7, other genetic differences may
contribute to susceptibility to polyoma virus–induced tu-
mors. In this connection, Benjamin and coworkers (31) re-
cently reported that an H-2k wild-derived inbred mouse
strain lacking endogenous Mtvs is susceptible to polyoma
virus–induced tumors. Interestingly, the frequency of
Vb61CD81 T cells in adult mice of this strain is lower than
that of resistant H-2k inbred mice. It would be valuable to
measure the magnitude of the MT389-specific CD81 T
cell response in infected neonatal mice of this wild-derived
inbred strain and assess the integrity of its effector activities.
The absence of ex vivo cytotoxic activity by MT389-
specific CD81 T cells in susceptible mice clearly compro-
mises the host’s ability to control polyoma virus infection.
T cell–mediated clearance of polyoma virus during acute
infection is associated with protection against outgrowth of
polyoma-induced tumors (32). This is easily envisioned for
H-2k mice where the dominant antipolyoma CD81 T cell
response is directed towards an epitope in MT, a nonstruc-
tural viral protein whose constitutive expression is required
both for efficient productive viral infection and mainte-
nance of cellular transformation (33–35).
Several mechanisms may be invoked to account for this
defect in CD81 T cell cytotoxic effector function. Compa-
rable TCR functional avidities between MT389-specific
CD81 T cells in resistant and susceptible mice argue against
major perturbations in the TCR signaling apparatus, as re-
ported for tumor-infiltrating and HIV-specific CD81 T
cells (36, 37). Partial anergy is also unlikely, as higher levels
of TCR occupancy by CD81 T cells are needed for trig-
gering IFN-g production than cytotoxic activity (38). Re-
cent studies suggest that incomplete maturation of virus-
specific CD81 T cells in vivo may be responsible for
impaired cytotoxic effector activity. HIV-specific CD81 T
cells, which exhibit weak cytotoxicity, have been shown to
concomitantly express low perforin levels and a pattern of
surface maturation markers suggestive of immature effector
cells (39). In addition, Spencer and Braciale (30) recently
described an influenza virus–specific memory CD81 T cell
population requiring multiple rounds of in vitro antigen
stimulation to promote their differentiation into CTL ef-
fectors. However, two lines of evidence argue against in-
complete differentiation of polyoma-specific CD81 T cells
in susceptible mice as an explanation for their lack of cyto-
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sistant and susceptible mice express similar levels of per-
forin. Second, MT389-specific CD81 T cells in resistant
and susceptible mice exhibit upregulated expression of cell
surface O-glycans, a phenotype tightly associated with
CTL activity (27). Taken together, these findings indicate
that in mice susceptible to polyoma virus–induced tumors
the dominant antipolyoma CD81 T cell response appears
to be fully armed with, but restrained from using, its cyto-
toxic effector activity.
The presence of CD81 T cells partially or completely
lacking antigen-triggered effector activity has been ob-
served in persistent viral infections and cancer-bearing hosts
(14, 39, 40). In these situations of chronic antigen expo-
sure, host mechanisms may come into play to intentionally
downregulate CTL activity to prevent widespread destruc-
tion of antigen-bearing cells. For persistent viruses with on-
cogenic potential, such as mouse polyoma virus, early ter-
mination of cytotoxic effector functionality by antiviral
CD81 T cells would clearly impair immune surveillance
against virus-induced neoplastic cells. Furthermore, as peak
MT389-specific CD81 T cell numbers differ only fourfold
between acutely infected neonatal mice having opposite
polyoma tumor susceptibilities, a fine balance likely exists
between the size of the initial antipolyoma CD81 T cell re-
sponse and the level of infectious virus that decides the fate
of CD81 T cell functional competence in vivo. Elucidation
of the in vivo mechanisms that control antigen-specific
CD81 T cell effector activity in the setting of persistent an-
tigen is essential for development of immunotherapeutic
strategies against viral oncogenesis.
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